Celldex Therapeutics (CLDX) Total Current Liabilities (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Total Current Liabilities of $51.5 million for Q1 2026, up 60.76% year-over-year from $32.0 million in Q1 2025, and up 0.94% quarter-over-quarter from $51.0 million in Q4 2025.
Celldex Therapeutics (CLDX) Total Current Liabilities (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $51.5 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 60.76% year-over-year to $51.5 million; the TTM figure through Mar 2026 stood at $51.5 million (up 60.76% YoY), while the FY2025 annual figure was $51.0 million, up 29.09% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $51.5 million, up from $51.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $51.5 million in Q1 2026, with the low at $14.6 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $29.9 million (2022), against an average of $29.9 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 106.72% in 2022, then slumped 47.76% in 2023.
- Celldex Therapeutics' Total Current Liabilities stood at $18.6 million in 2022, then surged by 67.25% to $31.1 million in 2023, then grew by 26.91% to $39.5 million in 2024, then grew by 29.09% to $51.0 million in 2025, then gained by 0.94% to $51.5 million in 2026.
- Business Quant data shows CLDX's Total Current Liabilities at $51.5 million in Q1 2026, $51.0 million in Q4 2025, and $46.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 61.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.33 Mn |
| Mar 31, 2026 | 51.47 Mn |
| Dec 31, 2025 | 50.99 Mn |
| Sep 30, 2025 | 46.47 Mn |
| Jun 30, 2025 | 32.96 Mn |
| Mar 31, 2025 | 32.02 Mn |
| Dec 31, 2024 | 39.50 Mn |
| Sep 30, 2024 | 32.09 Mn |
| Jun 30, 2024 | 27.66 Mn |
| Mar 31, 2024 | 26.29 Mn |
| Dec 31, 2023 | 31.13 Mn |
| Sep 30, 2023 | 27.84 Mn |
| Jun 30, 2023 | 15.65 Mn |
| Mar 31, 2023 | 15.22 Mn |
| Dec 31, 2022 | 18.61 Mn |
| Sep 30, 2022 | 16.29 Mn |
| Jun 30, 2022 | 29.95 Mn |
| Mar 31, 2022 | 14.56 Mn |
| Dec 31, 2021 | 16.53 Mn |
| Sep 30, 2021 | 14.18 Mn |